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ABSTRACT
Recent data implicate elevated transforming growth factor-β (TGFβ) signalling 
in BRAF inhibitor drug-resistance mechanisms, but the potential for targeting TGFβ 
signalling in cases of advanced melanoma has not been investigated. We show 
that mutant BRAFV600E confers an intrinsic dependence on TGFβ/TGFβ receptor 
1 (TGFBR1) signalling for clonogenicity of murine melanocytes. Pharmacological 
inhibition of the TGFBR1 blocked the clonogenicity of human mutant BRAF melanoma 
cells through SMAD4-independent inhibition of mitosis, and also inhibited metastasis 
in xenografted zebrafish. When investigating the therapeutic potential of combining 
inhibitors of mutant BRAF and TGFBR1, we noted that unexpectedly, low-dose PLX-
4720 (a vemurafenib analogue) promoted proliferation of drug-naïve melanoma cells. 
Pharmacological or pharmacogenetic inhibition of TGFBR1 blocked growth promotion 
and phosphorylation of SRC, which is frequently associated with vemurafenib-
resistance mechanisms. Importantly, vemurafenib-resistant patient derived cells 
retained sensitivity to TGFBR1 inhibition, suggesting that TGFBR1 could be targeted 
therapeutically to combat the development of vemurafenib drug-resistance.
INTRODUCTION
Malignant melanoma is the most aggressive form of 
skin cancer with around 55,500 deaths worldwide in 2012 
[1]. While primary localised melanoma may be cured by 
surgical removal alone, metastatic melanoma is associated 
with poor long-term prognosis. Somatic mutations that 
constitutively activate the RAS-RAF-mitogen activated 
protein kinase-extracellular signal-regulated kinase 
(RAS-RAF-MEK-ERK) signalling pathway are frequently 
detected in melanoma; mutations in BRAF and NRAS 
have been detected in approximately 50% and 20% of 
melanomas, respectively [2]. The identification of genetic 
drivers of melanoma [2] has led to the development of 
small-molecule inhibitors inhibitors (e.g. vemurafenib, 
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dabrafenib) (BRAFi), which selectively target mutant 
BRAF. Their use in the clinic has significantly increased 
survival of metastatic melanoma patients [3-5]. However, 
the development of drug resistance remains a significant 
problem with the vast majority of patients with advanced 
melanoma dying of drug-resistant disease. 
Numerous mechanisms of resistance to BRAF 
inhibitors have been described, many involving 
reactivation of the MAPK pathway (reviewed in [6]). As 
a result, the combined use of BRAF inhibitors with MEK 
inhibitors (e.g. cobimetinib, trametinib) has been proposed 
as a way to overcome the development of resistance [7-
9]. While this approach significantly improves patient 
survival (resulting in a median expected survival of 
approximately 25 months for eligible patients), the 
efficacy of combinatorial therapies which target the same 
signalling pathway ultimately may be limited because of 
augmented BRAF inhibitor drug resistance mechanisms or 
secondary mutations [10, 11]. 
Additionally, secondary epigenetic events that do 
not necessarily affect MEK/ERK activity can occur to 
limit the tumour cells’ dependence on the MAPK pathway, 
or restrict tumour immune surveillance. These resistance 
mechanisms include changes in the methylome affecting 
tumour cell apoptosis [12], increases in PI3K/AKT activity 
[13-15] and/or increases in receptor tyrosine kinase 
(RTK) signalling. For instance, loss of microphthalmia-
associated transcription factor (MITF) expression 
correlates with increased RTK expression and resistance 
[16]. Vemurafenib-resistance induced increases in EGFR 
signalling have been shown to activate an EGFR-SRC-
STAT3 signalling cascade in melanoma, and targeting 
this pathway using inhibitors of SRC inhibits growth of 
vemurafenib-resistant xenografts [17, 18]. 
As well as cell autonomous effects, drug-induced 
stimulation of melanoma-associated fibroblasts stimulates 
matrix remodelling and, in this case, signals via integrins 
to increase SRC and FAK activity. This change in the 
microenvironment promotes melanoma cell survival and 
provides a “safe haven” to enable emergence of drug-
resistant tumour cells [19]. Clearly, stromal remodelling 
and SRC activation have emerged as contributors to BRAF 
inhibitor resistance, and it is apparent that the therapy-
induced secretome is key in driving resistance. Increased 
transforming growth factor-beta (TGFβ) secretion may 
be part of the therapy-induced secretome, and has been 
implicated in both in vitro derived drug resistance [20] and 
in vemurafenib-resistant patient material [21]. Increased 
TGFβ signalling can result in an upregulation of EGFR 
and PDGFR [21], positioning TGFβ signalling upstream 
of well described vemurafenib-resistance associated RTK 
pathways. Despite this, the potential for TGFβ pathway 
inhibitors in combating BRAF kinase inhibitor resistance 
has not been studied to date. 
TGFβ ligand binds to the constitutively active high 
affinity type 2 serine/threonine kinase receptor TGFBR2 
which trans-phosphorylates and activates TGFBR1. 
As part of the canonical signalling pathway, TGFBR1 
phosphorylates and activates the intracellular signalling 
transcription factors SMAD2 and SMAD3, and following 
binding to SMAD4, the SMAD complex accumulates in 
the nucleus where it regulates target gene transcription. 
Additionally, TGFβ can signal via numerous non-
canonical pathways including RHO/ROCK, MAPK, and 
PI3-Kinase (reviewed in [22]). In normal melanocytes, 
TGFβ inhibits proliferation and DNA synthesis and 
induces melanocyte stem cell quiescence, however, 
melanoma cells are able to evade the tumour suppressive 
effects of TGFβ. TGFβ levels are elevated in the plasma of 
melanoma patients (regardless of their exposure to BRAF 
inhibitors), and increases in expression are associated with 
progressive disease [23]. The mechanisms of growth arrest 
and their evasion by melanoma cells, however, have not 
been fully characterised and are likely to be multi-factorial 
(reviewed in [24]). 
There is little evidence of mutation of TGFβ 
receptors in melanoma [25], so, it appears that with 
functional receptors and apparently intact SMAD function 
[26, 27], melanoma cells are able to evade growth 
suppressive effects of TGFβ while simultaneously utilising 
pro-tumourigenic functions of TGFβ. TGFβ signalling 
promotes migration of BRAF-transformed melanocytes 
in in vitro organotypic skin cultures [28] and is involved 
in metastasis of mouse melanoma cells to the bone through 
expression of tissue-specific genes known to promote bone 
osteolysis [26, 29]. In addition, melanoma cells engineered 
to over-express TGFβ exert paracrine effects on stromal 
fibroblasts whereby they secrete matrix components 
(including fibronectin, collagens, and tenascin) to promote 
melanoma tumour formation [30]. These observations 
are reminiscent of the vemurafenib-induced activation 
of melanoma-associated fibroblasts providing a “safe 
haven” for melanoma tumour cells, however, no link has 
been formally established between vemurafenib-induced 
fibroblast activation and TGFβ signalling.
In this study, we now provide evidence that 
melanoma cells are “hard-wired” to depend on 
autocrine TGFβ signalling through TGFBR1 for tumour 
establishment and clonogenicity. We show that the 
fundamental addiction of melanoma cells to TGFβ is: 
induced by the presence of mutant BRAF; mediated by a 
SMAD4-independent pathway; and correlates with TGFβ 
regulation of RHOA activity, thus providing support 
for the notion that non-canonical signalling pathways 
are key mediators of pro-tumourigenic TGFβ function 
in melanoma. Importantly, we also provide evidence 
that vemurafenib resistant patient-derived cells retain 
sensitivity to inhibitors of TGFBR1. TGFBR1 inhibitors 
block the enhanced proliferation of paradoxically activated 
PLX-4720 treated melanoma cells, and can be used to 
effectively inhibit metastatic melanoma in a zebrafish 
xenograft model. 
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RESULTS
Mutant BRAF confers TGFβ addiction
We demonstrated previously that autocrine 
signalling through TGFBR1, is required for transformation 
of rodent fibroblasts by oncogenic BRAF [31], but did not 
investigate this dependence in human models of activated 
RAS/RAF-driven cancer. Since mutational activation of 
BRAF is frequently observed in melanoma [2], we tested 
the susceptibility of immortalised mouse melanocytes 
stably transfected with either wild-type or mutant BRAF 
to inhibition by the TGFBR1 kinase inhibitor SB-431542. 
Unlike parental or wildtype BRAF transfected cells, 
melanocytes transfected with oncogenic V600E BRAF 
required TGFBR1 kinase activity for their proliferation 
since SB-431542 decreased cell numbers (Figure 1a). 
These data suggest that the presence of mutant BRAF in 
melanocytes confers a dependence (or addiction) on the 
TGFβ/TGFBR1 signalling pathway for cell proliferation. 
Similar results were observed in soft agar assays 
measuring anchorage independent growth (Figure 1b). We 
determined the amount of autocrine TGFβ produced by 
the transfected melanocytes, using a bioassay of NIH3T3 
cells stably transfected with a CAGA12-luciferase reporter 
construct (Supplementary Figure 1a). The dependence on 
TGFBR1 activity for colony formation did not correlate 
simply with an increase in latent autocrine TGFβ 
production following transfection with mutant BRAF (no 
active TGFβ was detectable without medium acidification) 
(Supplementary Figure 1b). There was also no elevated 
signalling via the TGFβ receptor-regulated intracellular 
signalling transcription factor, SMAD2 in SB-431542 
sensitive cells (Supplementary Figure 1c). 
We tested whether human cancer cells with 
activating mutations in MAPK pathway components 
were also dependent on TGFBR1 for growth. A panel of 
human tumour cell lines carrying wild type RAS/BRAF 
or mutations in BRAF, HRAS, KRAS or NRAS (details 
of all cell lines are given in Supplementary Table 1) were 
tested for sensitivity to SB-431542 (Figure 1c). Inhibition 
of TGFBR1 resulted in a range of cellular responses in the 
wildtype, H-, K-, and N-RAS mutant groups, such that any 
dependence on TGFBR1 for colony formation could not 
be predicted in cells carrying these mutations. However, 
consistent with data obtained in mouse melanocytes 
(Figure 1b), colony formation in all seven human cell 
lines carrying mutant BRAF was significantly inhibited 
(Figure 1c). Again, sensitivity to the TGFBR1 inhibitor 
did not correlate with levels of autocrine TGFβ production 
(Supplementary Table S2). The effect of SB-431542 was 
dose-dependent in low density 2D-culture assay conditions 
established to assess more accurately clonogenic potential, 
reaching statistically significant inhibitory concentrations 
at 10µM (Figures 1d and 1e). Similar dose dependent 
effects were seen in anchorage-independent soft agar 
assays (Figure 1f). We attempted to select out TGFBR1 
inhibitor-resistant cells following repeated rounds of 
treatment for over a month, but saw no evidence of 
outgrowth of refractory subpopulations or acquired-
resistance during this time frame (Figure 1g). Taken 
together these data suggest that cells with mutational 
activation of BRAF, require TGFBR1 for efficient colony 
formation and that TGFβ would predictably function as a 
tumour promoter. 
Autocrine TGFβ is required for in vivo melanoma 
xenograft tumour formation
Melanoma cells engineered to over-express TGFβ1 
have increased tumour forming ability [30]. To discover 
whether endogenous autocrine TGFβ expression is 
required for tumour formation, we generated ligand 
knockdown clones of A375(M2) cells using stably 
transfected shRNA constructs targeting TGFβ1. 
Knockdown of TGFβ1 to levels below 20pg per 1x105 
cells/hr (Figure 2a) was sufficient to decrease the ability 
of A375(M2) cells to form colonies in vitro (Figure 2b 
and Supplementary Figure 2a). In xenograft assays, 
ligand knockdown reduced the percentage of mice with 
palpable tumours at all recorded time-points (Figure 2c), 
and significantly reduced tumour growth (Figure 2d). 
Immunohistochemical (IHC) staining of xenograft sections 
revealed increased expression of the cyclin-dependent 
kinase inhibitor CDKN1A (p21CIP1) in tumours generated 
by TGFβ knockdown cells (Figures 2e and 2f). Elevated 
CDKN1ACIP1 expression was also observed following 
SB-431542 treatment of A375(M2) cells (Supplementary 
Figure 2b). 
So far, our data implicate autocrine TGFβ signalling 
through TGFBR1 as a critical factor in melanoma 
clonogenicity and tumour formation, however, it was 
important to rule out off-target effects of the inhibitor. 
We therefore assessed colony formation following 
transient transfection with two independent siRNAs 
targeting TGFBR1. TGFBR1 knockdown (Supplementary 
Figure 3a) reduced TGFBR1 protein expression and 
phosphorylation of SMAD2 in response to exogenous 
TGFβ (Figures 3a and 3b), and recapitulated the effect 
of chemical inhibition of the receptor. Colony formation 
and cell proliferation decreased following TGFBR1 
knockdown (Figures 3c, 3d, and Supplementary Figures 
3b and 3c), confirming that TGFBR1 is required for 
melanoma colony formation. 
To discover whether the canonical SMAD pathway 
is required for either melanoma cell colony formation 
or for the inhibitory response to SB-431542, transient 
knockdown of the co-SMAD, SMAD4 was performed. 
Knockdown of SMAD4 (Figure 3e) had no significant 
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Figure 1: BRAFV600E confers sensitivity to TGFBR1 inhibition. a., b. Melan-a cells expressing the indicated BRAF construct 
were seeded on plastic a., or in soft agar for cells able to form anchorage independent colonies (mutant BRAF only) b., in the presence of 
concentrations of SB-431542 as shown. The mean (± SEM) cell number after 6 days a. or colony number after 3-4 weeks b.were counted 
and presented as a percentage of the vehicle control. Data was pooled from n = 3-5 independent experiments each performed in triplicate. 
c. Cell lines with activating mutations in BRAF, HRAS, KRAS or NRAS or with wildtype BRAF/RAS were seeded in soft agar in the 
presence of 10μM SB-431542. Data is presented as a mean (± SD) colony number as a percentage of the vehicle control. Colony counts that 
were significantly different from controls following treatment with 10μM SB-431542 are indicated by (#) (TTEST, p < 0.05). SK-MEL-147 
cells showed no colony formation in the presence of 0.2% DMSO and were assigned a value of 1 to allow analysis. The proportion of cell 
lines whose colony formation was inhibited by SB-431542 by more than 1/3 within each group is indicated on the histogram (*). d.-g. 
Mutant BRAFV600E human melanoma cell lines A375(M2) (d-g) and Colo829 f. were treated with either vehicle control or the indicated 
concentrations of SB-431542. Colony growth on plastic d. or in soft agar f. were counted after 14 days and 4 weeks, respectively. e. Live 
cell imaging using an IncuCyte Zoom was used to determine the growth kinetics of A375(M2) cells seeded at low cell density (100 cells/
well of 96-well plate) and treated with SB-431542. The mean percent confluence (± SEM) of 4 images per well (n = 24 from a representative 
experiment) is shown. Statistical analysis was carried out by pairwise comparison using the compareGrowthCurves function in statmod 
(R project). The adjusted p value (p < 0.001) is shown g. A375(M2) cells were serially passaged in the presence of 10µM SB-431542 to 
select resistant cells. Surviving cells after each round of treatment were reseeded at low cell density. Cell counts were determined at the 
end of each treatment round, and the results expressed as the mean (± SD) cell number from 6 wells as a percentage of the control (solvent 
control treated cells). 
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Figure 2: Colony and in vivo tumour formation require the autocrine production of TGFβ1. A375(M2) clones stably 
expressing a Control shRNA, or a TGFβ1 shRNA were analysed for TGFβ1 production a. and seeded into soft agar assays b.. a. TGFβ1 
levels were analysed by ELISA and are expressed as the amount (pg) of TGFβ1 produced by 1x105 cells/hour. Data shown are the means ± 
SD (n = 3) . Colonies were counted and presented as the mean ± SD colony number (n = 3) b.. Statistical significance was measured using 
Students TTESTS (* = p < 0.05, ** = p < 0.01, *** = p < 0.001). (c-f) A375 (M2) clones, stably expressing either vector control or TGFβ1 
shRNA were subcutaneously injected into the flanks of CD1 nude mice and tumours were allowed to develop. Palpable tumours were first 
detected after 8 days and were measured for a further 21 days. c. The number of mice (as a percentage of injected mice) that had palpable 
tumours on the indicated day (sh-Control, n = 16. sh-TGFβ1, n = 24). Statistical significance was measured using Students TTESTS (* = p 
< 0.05, ** = p < 0.01). d. Tumour volumes (mm2, mean ± SEM) were estimated on the indicated days post injection (sh-Control n = 16, sh-
TGFβ1 n = 24). Statistical analysis was carried out using compareGrowthCurves (Statmod). e., f. sh-control and sh-TGFβ1 tumour sections 
were stained for CDKN1A and counterstained with haematoxylin (sh-control, n = 8. sh-TGFβ1, n = 9). Representative images are shown in 
e. and the quantification of the resultant images by histoscore are shown in f.. The horizontal bar indicates the median histoscore, the grey 
boxes and vertical bars indicate 95% CI and range, respectively. P value following statistical analysis using Mann-Whitney U-test is shown.
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effect on A375(M2) colony formation (Figure 3f) 
and significantly increased Colo829 cell proliferation 
(Figure 3g). These data suggest that SMAD4-dependent 
signalling is not necessary for colony outgrowth and may, 
in fact, repress colony growth in Colo829 cells. SMAD4 
knockdown also did not block the inhibitory effect of 
SB-431542 (Figure 3h), indicating that the mechanism 
of inhibition is SMAD4 independent. In case the levels 
of knockdown were not sufficient to accurately assess 
the contribution of SMAD4, we tested a mutant BRAF/
SMAD4 null cell line (HT29). These cells were also 
sensitive to TGFBR1 inhibition (Supplementary Figures 
4a and 4b) thus supporting our conclusion that functional 
SMAD4 is not necessary for inhibition of colony 
formation by SB-431542. 
We next considered any non-canonical signalling 
pathways that might be affected by TGFβ signalling 
in melanoma cells. We previously reported that a non-
canonical TGFβ/TGFBR1/RHOA signalling pathway 
is necessary for initiation and maintenance of rodent 
fibroblast BRAFV600E transformed cultures [31]. Thus, 
in mutant BRAF human melanoma cells, it seemed 
plausible that this pathway could be involved in 
regulating melanoma cell clonogenicity. SB-431542 
treatment reduced levels of active-GTP bound RHOA 
(Supplementary Figure 4c), while transfection of 
melanoma cells with the exoenzyme C3 transferase to 
inhibit RHOA [32] mimicked the effect SB-431542 
(Supplementary Figure 4d). In addition, overexpression 
of either constitutively active RHOA, or the constitutively 
active RHOA specific guanine nucleotide exchange 
factors ∆558LARG or onco-LBC (to activate endogenous 
RHOA) [33], blocked the effect of the TGFBR1 inhibitor 
on colony formation (Supplementary Figure 4e). These 
data are consistent with our previous findings in rodent 
fibroblasts. 
To gain further insight into the cellular pathways 
involved in the inhibition of colony formation, we 
analysed cells by microscopy for division and apoptosis, 
using BRDU incorporation or fluorogenic apoptosis 
reagents respectively. Initial experiments revealed that 
SB-431542 treatment significantly reduced BRDU 
incorporation but induced little apoptosis (Supplementary 
Figure 5a and data not shown). We questioned whether 
an apparently modest reduction in BRDU incorporation 
was sufficient to account for the dramatic reduction in 
colony formation and cell proliferation. To investigate 
in more detail, we generated A375(M2) cell lines stably 
transfected with an H2B-red fluorescent protein (RFP) 
fusion protein expression construct to enable kinetic single 
cell tracking using IncuCyte imaging. Imaging between 
days four and six of treatment (Supplementary Figure 
5b) showed a reduction in their number, and a significant 
increase in the length of time cells remained in interphase 
(Supplementary Figure 5c). There were slight increases in 
the mean number of cells that failed to enter into mitosis 
or detached upon treatment, but these differences did not 
reach statistical significance (Supplementary Figures 5d 
and 5e). TGFBR1 inhibition, therefore, predominantly 
affects the proportion of cells in S-phase, and significantly 
affects the clonogenic potential of BRAF mutant cells 
through effects on the cell cycle. 
BRAF inhibitor resistance 
The addiction of mutant BRAF melanoma cells to 
signalling through TGFBR1 suggests a potential novel 
therapeutic approach for mutant BRAF-driven cancers. 
Ideally, not only would a novel treatment be effective 
as a single agent without evidence of refractory disease 
(Figure 1), but the novel therapeutic drug would act in 
combination with existing therapies to enhance their 
efficacy or prevent the development of resistance. The 
current therapeutic modality for mutant BRAF metastatic 
melanoma is treatment with BRAF inhibitors vemurafenib 
or dabrafenib in combination with MEK inhibitors for 
suitable patients. However, the development of BRAF 
inhibitor-resistant disease through a variety of different 
mechanisms, including the paradoxical activation of the 
MAPK pathway, remains a significant clinical problem. 
To assess the potential for a combination therapy 
targeting both BRAF and TGFBR1, we first tested the 
sensitivity of previously drug naïve A375(M2) and 
Colo829 to the mutant BRAF kinase inhibitor PLX-
4720 in our clonogenic, low density assay conditions. As 
expected, at doses exceeding 250nM, growth of both cell 
lines was inhibited, however, at lower doses, we noted 
an unexpected significant increase in cell proliferation 
(Figures 4a, 4b and Supplementary Figure 6a). 
Suboptimal doses of PLX-4720 induced phosphorylation 
of ERK (Supplementary Figure 6b), and the enhanced 
proliferation of Colo829 (Figure 4c) and A375(M2) cells 
(data not shown) were abrogated by co-treatment with 
the MEK inhibitor PD184352 (Figure 4c). These data 
are consistent with low dose PLX-4720 paradoxically 
activating the RAS-MAPK pathway. Since both cell lines 
carry BRAFV600E and are wild type for RAS, the most 
likely interpretation is that low dose PLX-4720 relieves 
an inhibitory autophosphorylation [34]. Consistent with 
this hypothesis, low dose PLX-4720 did not promote the 
proliferation of three melanoma cell lines carrying wild 
type RAF/RAS (Supplementary Figure 7). Importantly co-
treatment of PLX-4720 treated mutant BRAF cells with 
SB-431542 (10µM) abolished the increase in cell growth 
caused by low dose PLX-4720 (Figures 4d and 4e). We 
quantified the effect on clonogenicity [35] and showed that 
not only did SB-431542 significantly reduce clonogenicity 
as a single agent, but that the significant increase in 
clonogenicity induced by PLX-4720 alone was reversed 
by SB-431542 (Figure 4f and Supplementary Figure 6c). 
This result was recapitulated by siRNA knockdown of 
TGFBR1 (Figure 4g). 
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Figure 3: TGFBR1, but not SMAD4, is required for clonogenicity of mutant BRAFV600E melanoma cells. A375(M2) a., 
c. and Colo829 b., d. cells were transiently transfected with a non-silencing control siRNA (NS) or two independent siRNAs targeting 
TGFBR1 (#1 and #2). a., b. Western blot analysis of lysates from untreated or TGFβ treated cells (2 hours) were included to confirm a 
reduction in TGFBR1 expression and decreased signalling via phospho-SMAD2 following TGFBR1 knockdown. c. A375(M2) knockdown 
cells were seeded into soft agar assays in the presence of either vehicle control (DMSO, 0.1%) or SB-431542 (10µM). Mean colony 
numbers (± SD) are given and significant [(*) p < 0.05] and non-significant (n.s.) changes in colony number determined by Student’s 
TTEST are indicated. d. Colo829 cells transfected for 48 hours with non-silencing, or TGFBR1 siRNA in triplicate were seeded in 6-well 
plates. Cells were fed by 50% media replacement every 2 days and cell proliferation determined after 11 days. Mean (± SD) cell number is 
given and analysed for statistical significance by Student’s TTEST compared to the non-silencing control. e. A375(M2) and Colo829 cells 
were transiently transfected with a non-silencing control siRNA (NS) or smartpool siRNA targeting SMAD4. Cell lysates were analysed by 
SDS-PAGE and western blotting for knockdown levels (f, g) Colony formation f. or cell proliferation g. was determined following SMAD4 
knockdown in A375(M2) and Colo829 cells, respectively. Statistical analysis was performed using Students TTEST and n.s indicates non-
significant and * indicates p < 0.05. h. A375(M2) cells were transiently transfected with smartpool siRNA targeting SMAD4, treated with 
either vehicle control (DMSO, 0.1%) or SB-431542 (10µM) and assayed by live cell imaging for drug sensitivity. Data shown are the means 
± SEM percent confluence of 9 wells (4 fields/well) from a representative experiment. Statistical analysis was performed using Students 
TTEST and n.s indicates non-significant and *** indicates p < 0.001.
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Figure 4: Low dose BRAF inhibitor (PLX-4720) enhances proliferation of drug naïve melanoma cells. a., b. Cell 
proliferation assays were carried out by live cell imaging (IncuCyte Zoom). Colo829 (1500 cells/well of 96-well pate) and A375(M2) 
cells (100 cells/well of 96-well plate) were seeded overnight and treated with PLX-4720 at the concentrations indicated. The mean percent 
confluence (± SEM) from 8 fields (Colo829) and 9 fields (A375M2) from a representative experiment is shown. c. Colo829 cells were 
treated with solvent control (DMSO, 0.1%), PLX-4720 (62.5nM), the MEK inhibitor PD184352 (2µM) or PLX-4720 + PD184352 (BOTH) 
and cell proliferation analysed by live cell imaging. The mean percent confluence (± SEM) from 24 fields across 6 wells in a representative 
experiment is shown. d. A375(M2) cells were assayed for cell proliferation for 8 days following treatment with inhibitors of both mutant 
BRAF (PLX-4720, 31.25 nM) and TGFBR1 (SB-431542, 10µM). Statistical analysis was performed using Students TTEST and * = p < 
0.05 and *** = p < 0.001. e. Colo829 cells (40000/10cm dish) were seeded overnight prior to treatment with solvent control (DMSO, 0.1%), 
PLX-4720 (62.5nM), SB-431542 (10µM) or PLX-4720 + SB-431542. Cells were fed by 50% media replacement every 3 days and colonies 
were fixed, stained and counted at day 16. Statistical analysis was performed using Students TTEST and * = p < 0.05 and ** = p < 0.01. f. 
Clonogenicity assays with A375(M2) cells seeded at 1 and 3 cells/well were carried out with vehicle control, SB-431542 (10µM), PLX-
4720 (31.25nM) or both drugs (BOTH) for 14 days. Representative plates stained with SRB are shown (left panel). The mean surviving 
fraction of colonies (± SD) (right panel) was determined (as described in the methods section) from plates seeded with both 1 and 3 cells/
well from independent replicate experiments (n = 4). Statistical analysis was performed using Students TTEST and * = p < 0.05 and ** = 
p < 0.01. g. A375(M2) cells were assayed for cell proliferation following transfection with non-silencing (NS) siRNA or siRNA targeting 
TGFBR1 followed by treatment with PLX-4720 (31.25nM). Statistical analysis was performed using Students TTEST and * = p < 0.05, ** 
= p < 0.01, *** = p < 0.001 and n.s = not significant. 
Oncotarget9www.impactjournals.com/oncotarget
To investigate further the potential for TGFBR1 
inhibitors to prevent vemurafenib resistance, we tested 
both in vitro derived resistant lines (A375R), and patient 
derived vemurafenib-resistant recurrent tumour cells for 
sensitivity to SB-431542 (10µM). Patients #2 and #35 
(stage IV) achieved a partial response having received 
vemurafenib for 3 months. Patient #5 (stage IV) had 
progressive disease and received vemurafenib for 2 months 
(Supplementary Table 1). The growth of vemurafenib-
naïve A375 (Figure 5a) and patient tumour derived 
cells (Patient#1) (Figure 5b) [18] were both inhibited 
by SB-431542. Importantly, in vitro derived PLX-4720 
resistant A375R cells (cultured in the presence of 1µM 
PLX-4720) were growth inhibited by SB-431542 (Figure 
5a). The patient-derived vemurafenib resistant cells had 
readily detectable levels of phosphorylated SMAD2 that 
were reduced on SB-431542 treatment, indicating that 
they all had active autocrine TGFβ signalling (Figure 
5c). In addition, all vemurafenib-resistant lines derived 
from patients were growth inhibited by SB-431542 in 
proliferation assays (Figure 5d) and in longer term colony 
formation assays (Figure 5e). Vemurafenib resistant cells 
therefore retain their sensitivity to inhibitors of the TGFβ 
signalling pathway. 
Several reports indicate that the development of 
resistance to BRAF kinase inhibitors may be associated 
with signalling through SRC-family kinases, and that 
resistance can be overcome by inhibition of SRC 
activity [17-19, 36]. We therefore tested whether TGFβ 
signalling was associated with SRC phosphorylation in 
A375(M2) and Colo829 cells (Figure 6). We noted that 
phosphorylated-SRC levels increased during the five day 
incubation period in cells initially plated at low density. 
SB-431542 (10µM) (Figure 6a) and TGFBR1 siRNA 
(Figure 6b) prevented any accumulation of phosphorylated 
SRC during the time course, and SB-431542 blocked an 
increase in phospho-SRC levels induced by low-dose 
PLX-4720 in A375(M2) cells (Figure 6a). An important 
implication of these data is that inhibition of TGFBR1 
signalling may restrict signalling through a known 
mediator of vemurafenib resistance. 
Zebrafish embryo xenograft metastasis model
So far, our murine xenograft assays, and inhibition 
of clonogenic potential of melanoma cells in low cell 
density 3D and 2D culture systems, suggest that TGFBR1 
inhibitors would be effective in preventing establishment 
of disease. To further examine whether TGFBR1 
inhibitors could effectively treat established cell cultures, 
we seeded cells at low cell density and progressively 
delayed addition of drug throughout the lag phase of 
cell growth. SB-431542 was effective if administered 
during the lag phase, but delaying treatment until the 
cells start to exit the lag phase considerably reduced its 
efficacy (Supplementary Figure 8a). Similarly, seeding 
cells at higher cell numbers also reduced the efficacy of 
SB-431542 in both vemurafenib naïve and resistant cells 
(Supplementary Figure 8b). Given these observations, we 
posit that cell:cell contact and/or allowing the secretion 
of growth factors or matrix components has a protective 
effect against TGFBR1 inhibitors; the implication is that 
TGFBR1 inhibitors might not be useful as first line, single 
agents or as debulking therapeutic agents in established 
solid tumours. Nevertheless, the dependence of melanoma 
cells on TGFBR1 for clonogenicity suggests that TGFBR1 
inhibitors could be effective in preventing spread or 
outgrowth of micrometastases. To test this hypothesis 
we used a zebrafish embryo metastasis model [37, 38] 
to visualise and quantify numbers of invasive melanoma 
cells. This model has been used successfully to examine 
the effect of SB-431542 on breast cancer cell invasion 
[39]. We generated stable TGFBR1 knockdown A375(M2) 
cell lines using LMP-TGFBR1 shRNA plasmids, which 
had reduced TGFBR1 protein expression and reduced 
capacity to signal (Figure 7a) as well as reduced ability 
to form colonies on plastic (Figure 7b). The stable lines 
were labelled with the mCherry fluorophore, injected into 
the Duct of Cuvier (DoC) of zebrafish embryos and the 
numbers of invasive cells in the avascular tail fins were 
analysed. Representative con-focal images of metastatic 
spread into the tail fin are shown in Figure 7c. Control 
non-silencing (NS) A375(M2) cells were capable of 
metastatic spread into the fish fin (arrows indicate micro-
metastases). Using doses of 1µM SB-431542 (SBi), we 
observed a significant decrease in the ability of SB-431542 
treated NS cells to invade. Stable TGFBR1 knockdown 
also reduced colonisation of zebrafish tissue (Figure 7d). 
Our data overall suggest that TGFBR1 inhibitors would 
reduce the metastatic burden in BRAF mutant melanoma 
by preventing invasion and/or outgrowth of metastatic 
colonies. 
DISCUSSION
The outcome for patients with advanced melanoma 
has improved dramatically in recent years. The 
development of targeted therapy of the MAPK pathway, 
and advances in immunotherapy have resulted in 
improvements in median survival from 9 months to 25-31 
months. However, long-term prognosis remains uncertain. 
For targeted therapy using BRAFi, drug resistance 
mechanisms identified to date are numerous, and there is 
no established effective second-line targeted therapy for 
patients progressing on combination BRAFi + MEKi. 
Often, drug-resistance mechanisms involve induction of 
either an autocrine, or a paracrine, drug-induced secretome 
which helps to promote expansion and dissemination of 
the drug-resistant cells [15] and/or protect potentially 
sensitive tumour cells from the inhibitory effects of the 
chemotherapeutic agent [15, 19, 21]. Phosphorylated 
ERK and SRC are frequently elevated in resistant tumours 
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Figure 5: Patient-derived BRAF inhibitor resistant tumour cells are sensitive to TGFBR1 inhibition. a., b., d. Cells 
seeded at 500 - 800/well in 96-well plates were assayed for proliferation in the presence of solvent control (DMS0, 0.1%) or SB-431542 
(10µM). A375 cells and the PLX-4720 resistant derivative A375R a., patient-derived drug naïve b., and vemurafenib resistant patient 
tumour derived cell lines c., d. were tested. Vemurafenib resistant patient-derived recurrent tumour cells shown in d. were routinely 
cultured in the presence of 1µM PLX-4720. Data is presented as the mean percent confluence (± SEM) from 6 replicate wells, 4 fields/well 
from representative experiments. Statistical analysis was performed using compareGrowthCurves (Statmod). c. Lysates from vemurafenib 
resistant patient-derived recurrent tumour cells were assayed by western blot for constitutive TGFβ signalling and the response to TGFBR1 
inhibition (4 hours, 10µM SB-431542). Phosphorylation of SMAD2 was used as a marker of TGFβ activity. e. Vemurafenib resistant 
recurrent melanoma patient cell lines were seeded in 10cm dishes at 1000 cells (Patient#35, n = 4), 16,000 cells (Patient 5, n = 4) and 1000 
cells (Patient#2, n = 3) per dish and treated with solvent control or SB-431542 (10µM). Colonies were stained, counted and the mean colony 
number ± SD presented. Statistical analysis was carried out by Student TTEST, * = p < 0.05, *** = p < 0.001.
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[18] suggesting that paradoxical activation of the MAPK 
pathway and growth factor signalling are involved in 
resistance development. In this study we investigated the 
potential of targeting TGFβ1 as second-line therapy for 
advanced melanoma. 
We found that autocrine TGFβ signalling through 
TGFBR1 is an intrinsic requirement for the clonogenic 
potential of mutant BRAF transformed cells, indicating 
that mutation of BRAF may be useful as a biomarker for 
TGFβ tumour promoting activity in melanoma. Although 
TGFβ levels are elevated post-vemurafenib treatment [20, 
21], our data suggest that a TGFβ/TGFBR1-dependent 
state is an adaptation to the presence of mutant BRAF. 
Thus, with pro-tumourigenic autocrine TGFβ signalling 
pathways having already been established, elevated levels 
of signalling during therapy are perhaps more readily 
selected for than would otherwise be the case. How the 
initial switch from tumour suppressor to tumour promoter 
function of TGFβ in melanocytes is mediated by mutant 
BRAF remains to be determined. 
Our in vitro assays were specifically designed to 
mimic conditions of cellular stress (i.e. low density 2D 
and anchorage independent colony formation assays) 
to more accurately assess the clonogenic potential of 
melanoma cells and their cancer stem-cell like properties. 
TGFBR1 inhibition was highly effective in inhibiting 
growth of both naïve and vemurafenib-resistant cells when 
administered during the lag phase of growth; less so when 
cell seeding numbers were increased. The implication of 
these data is that targeting TGFβ/TGFBR1 may not be 
an effective therapeutic strategy in established tumours. 
A secondary consideration is that TGFBR1 inhibition 
affected proliferation of the tumour cells without inducing 
apoptosis, and so may not result in significant tumour 
shrinkage. As a consequence, we predicted that inhibiting 
TGFβ/TGFBR1 signalling would more likely be effective 
in preventing tumour metastasis and outgrowth of 
micrometastasis, rather than reducing established tumour 
burden. Indeed, our murine and zebrafish xenograft 
models show that targeting autocrine TGFβ secretion 
and TGFBR1 kinase activity inhibits xenograft tumour 
establishment in mice and prevents metastatic spread in 
zebrafish tissues. TGFBR1 inhibitors therefore may have 
potential as an adjuvant therapy in high risk, resected 
disease, or a maintenance therapy in patients responding 
to BRAF inhibitors. The inhibition of glioblastoma cancer 
initiating (stem) cells by TGFBR1 inhibitors [40, 41] is 
consistent with our data, and provides support for our 
conclusion that TGFBR1 activity is required for melanoma 
stem-cell like properties.
Given the vast number of context specific genes 
regulated by TGFβ, it is likely that a number of different 
downstream effectors will mediate the autocrine TGFβ-
induced promotion of melanoma cell growth and 
drug-resistance. We showed that although melanoma 
cells rely on TGFBR1 kinase activity, they do not 
require SMAD4 for either colony formation, or for the 
response to TGFBR1 inhibition. Signalling via RHOA, 
however, rescued the effect of SB-431542 which is both 
consistent with our previous analysis of rodent fibroblast 
transformation [31], and with a role for TGFβ-activated 
non-canonical signalling pathways in this response. The 
establishment of an adaptive autocrine TGFβ/TGFBR1 
signalling pathway through RHOA following BRAF 
mutation may be necessary to overcome CDKN1A 
expression and growth arrest induced as a response 
to oncogenic stress [31, 42]. Consistent with this are 
our data showing CDKN1A induction by disrupting 
TGFβ signalling both in vitro and in vivo (Figure 2 and 
Supplementary Figure S2). Interestingly, inhibition of 
Figure 6: SB-431542 treatment and TGFBR1 knockdown inhibit phosphorylation of SRC. a. A375(M2) and Colo829 
cells were seeded at low density in 10cm dishes in the presence of SB-431542 (SBi) (10µM) and/or PLX-4720 (62.5nM and 31.25nM for 
A375(M2) and Colo829 cells respectively). Samples treated with both SB-431542 and PLX-4720 are labelled (Both). At Day 1 and Day 5, 
cells were harvested and analysed by SDS-PAGE and western blotting using the antibodies indicated. b. A375(M2) cells were transfected 
with non-silencing siRNA or siRNAs (#1 and #2) targeting TGFBR1. Cells were seeded at low cell density and after five days harvested 
for SDS-PAGE analysis and western blotting for the proteins indicated.
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Figure 7: TGFBR1 is required for tumour cell metastasis in xenografted zebrafish. a., b. A375(M2) cells stably transfected 
with a non-silencing shRNA control plasmid or two independent shRNA vectors targeting TGFBR1 were assessed by western blotting for a 
reduction in TGFBR1 expression and signalling in response to exogenous TGFβ addition a. and colony formation b.. c. Cells described in 
a. were labelled with mCherry and implanted into the Duct of Cuvier of zebrafish at 2 days post-fertilization (dpf). SB-431542 (1µM) was 
added to the egg water of the non-silencing (NS) + SB-431542 group. Confocal images were taken at 4 days post implantation (dpi). Arrows 
indicate invasive tumour cells, scale bar: 100 µm. d. Invasive cell numbers in tail fin of each zebrafish in each group. Statistical analysis was 
performed using one-way analysis of variance (ANOVA) followed by the Tukey’s method for multiple comparison *** p < 0.001. Data are 
combined from four independent experiments and the total number of embryos (n) in each group is indicated.
Oncotarget13www.impactjournals.com/oncotarget
ROCK (using Y27632), a downstream target of RHOA 
signalling, also induces CDKN1A in melanoma [43], 
and ROCK1 has been identified as a potential candidate 
for combinatorial therapy with BRAF inhibitors. In 
these studies inhibition of ROCK1 sensitises melanoma 
cells to PLX-4720 [44]. Our data now suggest that the 
involvement of ROCK1 in resistance mechanisms is 
potentially a result of TGFβ/TGFBR1/RHOA signalling. 
Although the SMAD-dependent induction of RHO GEFs 
has been described in other studies, [45, 46] how TGFBR1 
directly activates RHOA in melanoma cells in a SMAD-
independent manner is unclear at present. 
Several other TGFβ target genes have been 
implicated in melanoma biological responses. Melanoma 
cells exposed to the high levels of exogenous TGFβ 
present in bone, upregulate osteolytic genes (including 
IL-11, PTHrP, and CTGF) which may aid more effective 
colonisation of this metastatic niche. Blocking receptor 
function by over-expression of the natural inhibitor 
SMAD7 extended survival of mice xenografted with 
SMAD7 expressing melanoma cells. However, a causal 
role for the TGFβ-regulated osteolytic genes in bone 
metastasis was not directly demonstrated [26]. Similarly, 
the balance between the TGFβ target gene GLI2 and the 
melanocyte specific isoform of MITF (M-MITF) appears 
important for invasion through matrigel in vitro, with 
high GLI-2/low M-MITF correlating with invasion. 
However, these expression profiles were independent of 
BRAF mutation status and did not correlate with either 
proliferation in vitro or with subcutaneous xenograft 
tumour establishment [47]. We suspect that TGFβ target 
genes induced by exogenous TGFβ exposure may be quite 
different from those genes regulated by non-canonical 
signalling as a result of autocrine TGFβ ‘addiction’ 
established following BRAF mutation. Further work to 
identify which are the key TGFβ target genes involved in 
both promoting these stem-cell properties, and in driving 
drug-resistance, is underway and we expect that these 
studies will suggest novel, selective therapeutic targets.
We show that drug-naïve melanoma cells are 
growth promoted by low-dose PLX-4720, likely by 
paradoxical activation of the MAPK pathway. This may 
have important implications clinically, since low doses 
of bioavailable BRAFi reaching some tumour tissue 
could actually potentiate tumour growth. Importantly, 
we show that both paradoxically activated, previously 
drug naïve cells, as well as vemurafenib resistant cells, 
retain sensitivity to TGFBR1 inhibitors. In addition, 
SB-431542 prevented phosphorylation of SRC which 
is frequently associated with vemurafenib resistance, 
suggesting that TGFBR1 inhibitors would prevent relapse 
with vemurafenib-resistant metastases. How SB-431542 
regulates SRC activation is currently under investigation 
in our laboratory. It will be important to test the sensitivity 
of BRAFi/MEKi resistant cells derived from patients 
treated with combination therapy when established. 
Nevertheless, we predict that targeting an independent 
signalling pathway may have some advantages over 
combination therapies which target different components 
of the same signalling pathway. In addition, blocking the 
immunosuppressive effects of TGFβ could potentiate the 
efficacy of immune based therapeutics. Since dependence 
on TGFβ signalling appears to be universal in mutant 
BRAF melanoma cells, targeting TGFβ or downstream 
effectors may also provide useful therapeutic options for 
blocking metastatic outgrowth of vemurafenib refractory 
disease which occurs in approximately 20% of patients 
receiving treatment. There are currently a number of 
TGFβ pathway inhibitors progressing through Phase 1-3 
clinical trials [48]. The small molecule TGFBR1 inhibitor 
Galunisertib is being evaluated in cancer patients with 
unmet need. This inhibitor is deemed tolerable, with an 
acceptable margin of safety when administered using 
intermittent dosing regimens [49], demonstrating that 
TGFBR1 inhibitors are suitable for clinical use and may 
provide new opportunities for therapy of BRAF-inhibitor 
resistant cancer. 
MATERIALS AND METHODS
Western blotting
Cell lysates were analysed by SDS-PAGE using 
the following antibodies: PO4-SMAD2 (Ser465/467) 
(rabbit polyclonal, #3101, Cell Signalling Technology 
[CST]), SMAD2 (mouse monoclonal, C16D3, CST), 
SMAD2/3 (mouse monoclonal, Clone 18, BD transduction 
Laboratories), SMAD4 (mouse monoclonal, B-8, Santa 
Cruz Biotechnology), TGFBR1 (rabbit polyclonal, V-22, 
Santa Cruz Biotechnology), CDKN1A (rabbit polyclonal, 
C19, Santa Cruz Biotechnology), RHOA (mouse 
monoclonal, 26C4, Santa Cruz Biotechnology), PO4-
SRC (Tyr416) (rabbit monoclonal, D49G4, CST), SRC 
(rabbit monoclonal, 36D10, CST), PO4-p44/p42 MAPK 
(ERK1/2) (Thr202/Tyr404) (rabbit polyclonal, #9101, 
CST), p44/p42 MAPK (ERK1/2) (rabbit polyclonal, 
#9102, CST), β-actin (mouse monoclonal, AC-74, Sigma). 
Secondary HRP-conjugated antibodies (Dako) and 
enhanced chemiluminescence (GE Healthcare) was used 
to detect bound antibody.
Cell culture
Details of the cell lines and media supplements used 
are shown in Supplementary Table S1. All cells lines were 
tested regularly for mycoplasma contamination by the 
Institute’s mycoplasma testing service. Patient derived cell 
lines were passaged for approximately 1 month. Where 
indicated the cells were transfected with Lipofectamine 
or Lipofectamine 2000 (Invitrogen) using the following 
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plasmids; pRK5 C3-transferase and pEF-Flag LARG 
∆558 (kind gifts of R. Grosse), pRK5-RhoA V14 (kindly 
supplied by Alan Hall), pSR-Flag onco LBC (kindly 
supplied by Mike Olson), or pSuper-TGFβ1. LMP-
scrambled non-silencing (NS) and LMP-TGFBR1 shRNA 
constructs were generated in house with the following 
hairpin sequences: 
NS - 5’ 
CGAGAAGGTATATTGCTGTTGACAGTGAGCGACT 
CATAGCGATGTGAACTCAATAGTGAAGCCACAGA 
TGTATTGAGTTCACATCGCTATGAGCTGCCTACTG 
CCTCGG -3’; 
TGFBR1#1 - 5’ TCGAGAAGGTA 
TATTGCTGTTGACAGTGAGCGACTCATAGAGAT 
TTGAAATCAATAGTGAAGCCACAGATGTATTGAT 
TTCAAATCTCTATGAGCTGCCTACTGCCTCGG -3’; 
TGFBR1#2 - 5’ TCGAGAAGG 
TATATTGCTGTTGACAGTGAGCGACAGTGTAATA 
AAGTCAATTAATAGTGAAGCCACAGATGTATTAAT 
TGACTTTATTACACTGCTGCCTACTGCCTCGG. -3’.
Cells were transfected with either Oligofectamine or 
HiPerFect (Qiagen) to introduce, at a final concentration 
of 20 - -50nM, the following siRNA; allstars negative 
control, TGFBR1 [HS_TGFBR1_6 (TGFBR1#1) and 
HS_TGFBR1_7 (TGFBR1#2) (Qiagen)] or SMAD4 
(Dharmacon smartpool). Mock transfections (no siRNA) 
were included in each experiment. A375(M2) pSuper 
or pSuper-TGFβ1 stable cell lines were selected and 
maintained in 0.6mg/mL puromycin. A375(M2) histone 
H2B-RFP stable cell lines were selected and maintained in 
800µg/mL G418, and LMP-scrambled or LMP-TGFBR1 
shRNA derivatives were maintained in 800µg/mL G418 
plus 1µg/mL puromycin. Where indicated the cells were 
treated with SB-431542 (Tocris) [50],  PLX-4720 (Selleck 
Chemicals) or PD184352 (Cell Signalling) (prepared in 
DMSO).
Soft agar assay
Soft agar assays were carried out essentially as 
previously described [31]. Briefly, six well plates were 
coated in 2mLs of media supplemented with 0.9% low 
melting point agar (Invitrogen). 2mL cells (1x104/mL) in 
media supplemented with 0.45% low melting point agar 
were overlaid with either SB-431542 or vehicle control. 
Wells were fed twice weekly for 2-4 weeks, and the 
number of colonies ( > 80μm in diameter) in nine fields of 
view was scored using an Olympus CKX41 microscope, 
fitted with a 4X objective and an eyepiece graticule 
(250μm gradations). Statistical analyses were carried out 
by Students TTEST unless stated otherwise. 
Proliferation assay
Cell proliferation kinetics were either monitored 
using an IncuCyte ZoomTM imaging system and 
software (percent confluence) (Essen Biosciences), or by 
trypsinisation and cell counts using a Casy cell-counter 
(model TT, Innovatis).
Colony formation and clonogenicity assays
Colony formation: Cells were seeded in 10cm 
dishes at an appropriate density to form approximately 
250 discrete colonies after 2-3 weeks in culture. Colonies 
were fixed in methanol and stained with toluidine blue/
borax solution for counting. 
Clonogenicity: Cells were seeded overnight at 
1 and 3 cells/well in 60 wells of a 96-well plate, prior 
to treatment. Wells were fed twice weekly, and wells 
examined by light microscopy. After approximately two 
weeks, media was removed, colonies fixed in methanol 
and stained with 0.4% (w/v) sulforhodamineB (SRB)/1% 
acetic acid. Colonies > 50 cells in size were counted, and 
the plating efficiency and surviving fractions after drug 
treatment determined according to Franken et al [35]. 
TGFβ1 ELISA
The TGFβ1 assay has been described previously 
[31]. Briefly, cells were cultured in media containing 
0.1% FBS for 24 hours. Media was harvested and the 
cells trypsinized and counted. The media was acid treated 
to activate latent TGFβ, and TGFβ1 levels determined by 
ELISA using anti-TGFβ1 (MAB1835) (capture antibody) 
and biotinylated anti-TGFβ1 (BAF240) (detection 
antibody). Recombinant hTGFβ1 (Peprotech) was used as 
a standard. Results were expressed as TGFβ1 produced 
per 1x105 cells/hour.
Mouse xenografts
Nude mouse subcutaneous xenograft experiments 
were performed according to Home Office guidelines and 
were approved by the local research and ethics committee 
(BICRLREC). 1x106 cells were injected subcutaneously 
into the flank of CD1 nude mice (n = 8) (Charles Rivers). 
Palpable tumours were observed 8 days post-injection 
and tumour volumes were calculated using calliper 
measurement and the formula V = (E2xA)/2 where E = 
shortest and A = the longest diameter measurement.
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Immunohistochemistry
Sections from formalin, paraffin embedded, 
pSuper (Control shRNA) or pSuper-TGFβ1 shRNA 
tumours were stained for CDKN1A (M19, Santa Cruz 
Biotechnology) using an Envision kit (Dako) according 
to the manufacturer’s instructions. The sections were 
counter stained with Haemotoxylin and were scored for 
CDKN1A expression. One representative field of view 
(that contained a minimum of 350 cells) was scored 
(blind) for each tumour. 
IncuCyte zoom and analysis
An IncuCyte Zoom live cell imaging microscope 
(Essen Biosciences) with 10x objective and data 
management software was used to monitor kinetic cell 
proliferation. The mean ± SEM percent confluence from 
four phase-contrast images/well, with a minimum of 3 
replicate wells/treatment was determined according to 
software processing definitions as recommended by the 
manufacturer. Statistical analysis was carried out using 
Graphpad software and pairwise comparisons using the 
compareGrowthCurves function (statmod, R project, 
10,000 permutations). 
Embryo preparation and tumor cell implantation
Zebrafish and embryos were raised, staged and 
maintained according to standard procedures. The 
Institutional Committee for Animal Welfare of the Leiden 
University Medical Center (LUMC) approved this study. 
Tg(Fli1:GFP) zebrafish embryos were dechorionated at 
two days post-fertilisation (dpf). Single cell suspensions 
of melanoma cells were prepared in PBS and kept at 
4°C before implantation. The cell suspension was loaded 
into borosilicate glass capillary needles (1 mm O.D. 
× 0.78 mm I.D.; Harvard Apparatus) and the injections 
were performed using a Pneumatic Picopump and a 
manipulator (World Precision Instruments, Stevenage, 
UK). Dechorionated embryos were anaesthetised with 
0.003% 3-amino benzoic acid ethyl ester [tricaine, 
(Sigma)] and mounted on 10 cm Petridishes coated with 
1% agarose. Approximately 200 cells were injected at the 
duct of Cuvier (DoC). Implanted zebrafish embryos were 
maintained at 33°C. Zebrafish in the Non-Silencing (NS) 
+ SB431542 group were treated with 1µM SB-431542 
added to the eggwater. All implantations were repeated at 
least three times with at least 30 embryos per group. 
Microscopy and analysis of zebrafish
Zebrafish embryos were fixed with 4% 
paraformaldehyde for two hours at room temperature. 
Embryos were imaged in PBS/0.1% Tween-20 (Merck, 
Amsterdam, Netherlands) using a Leica SP5 STED 
confocal microscope (Leica, Rijswijk, Netherlands). 
Confocal stacks were processed for maximum intensity 
projections with Image J. Images were adjusted for 
brightness and contrast, and overlays created using Adobe 
Photoshop CS6. Statistical analysis was performed using 
Prism 4 software (GraphPad, La Jolla, USA). Results are 
expressed as the mean ± SD. One-way analysis of variance 
(ANOVA) were performed followed by the Tukey’s 
method for multiple comparison. P < 0.05 was considered 
to be statistically significant (*0.01  <  P < 0.05; **0.001 
<  P < 0.01; *** P < 0.001). In one experiment the results 
were scored blinded; all results were confirmed by an 
independent observer.
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